Tommaso Barba, a PhD candidate at Imperial College London’s Centre for Psychedelic Research, put a number on it this week that the field has been circling for years: 39%. In nearly 600 patients with treatment-resistant depression, episodes averaging more than three years in duration, 39% of those receiving a 25mg dose of psilocybin achieved a clinically meaningful reduction in depressive symptoms by week 6 and held that response through week 26. A second dose pushed nearly 30% of week-6 responders into remission. Serious adverse events were essentially equivalent across groups: 5.7% versus 6.3%, with no new safety signals. Barba’s read is direct: psilocybin could be an approved antidepressant within a year, with Compass Pathways already in rolling NDA submission and FDA priority review potentially compressing the clock to one to two months post-filing.

That same week, Alan K. Davis at Ohio State’s Center for Psychedelic Drug Research and Education announced the publication of the first peer-reviewed clinical trial of psilocybin-assisted therapy in veterans with treatment-resistant PTSD, in Nature Communications Medicine. The sample was small, n=12, but the signal was not. Nathan Sepeda, Director of Data and Analytics at the Johns Hopkins Center for Psychedelic and Consciousness Research, contextualized the results precisely: one month post-treatment, 75% of participants no longer met diagnostic criteria for PTSD, and 83% showed a clinically meaningful response, defined as a reduction of at least 15 points on the CAPS-5 scale. Notably, participant expectancy of treatment effects was not predictive of symptom change, which undercuts the most persistent methodological objection lodged against psychedelic trial outcomes.

Two data releases. Two independent research centers. One convergent signal. The evidentiary case for psilocybin-assisted therapy has entered a different phase of the argument.

The Wicked Problem No One Is Pricing In

But here is where the field risks a category error. The instinct, understandable after years of regulatory skepticism and scientific marginalization, is to treat FDA approval as the finish line. Compass files its modular submission, the Priority Review Voucher compresses the clock, psilocybin launches in the first half of 2027, and the problem is solved. That framing collapses the moment you try to operationalize it. Approval answers the question of whether psilocybin can work. Guideline infrastructure answers the question of how clinicians are supposed to use it, when, in whom, with what co-interventions, and what to do when it goes sideways.

Helene Speyer, a senior psychiatric researcher at Copenhagen’s Region Hovedstadens Psykiatri, published a paper this week with co-authors Awais Aftab, Marte Ustrup, and David Roe arguing something that should stop the field cold. Clinical guidelines, she and her colleagues write, are engineered for “tame” problems: defined populations, measurable outcomes, predictable mechanistic pathways. Psychedelic-assisted therapy generates “wicked” problems, where evidence is incomplete, values differ, goals conflict, and no single right answer exists. Their argument is that the reflex to produce an algorithmic guideline for psilocybin therapy will not solve the problem. It will paper over it.

Consider what “wicked” actually looks like in a post-approval psilocybin clinic. A veteran with treatment-resistant PTSD, per the Ohio State data, spends approximately eight hours in preparatory therapy before receiving psilocybin. Sepeda noted in his post that researchers observed a small but statistically significant reduction in PTSD severity during that preparatory period alone, followed by a much larger reduction after drug administration. The therapeutic effect is therefore a combined function of the relationship, the preparation, the drug, and the integration work that follows. Which element does a prescribing physician bill for? Which element does a payer cover? Which element becomes the standard of care, and who enforces it when a community mental health clinic cannot afford eight hours of therapist time per patient?

These are not edge cases to be worked out post-launch. They are the clinical reality of the treatment, baked into every published trial protocol. Guidelines that ignore the therapy and focus only on the molecule will produce a degraded version of what the trials actually tested.

What the Remission Numbers Obscure

Stacey Bradbury Armstrong at Ohio State’s CPDRE flagged a critical data gap in the veteran trial results: the three- and six-month follow-up outcomes are still underway. That caveat matters more here than in a conventional pharmacotherapy trial. The 75% remission rate at one month is a striking number, and it deserves the attention it is getting. But psilocybin’s durability profile, particularly under real-world conditions without the structured integration support of a clinical trial, remains the open question. Sepeda acknowledged the same limitation directly, noting that larger controlled studies are needed to disentangle the relative contributions of therapy and drug.

This is where the counterintuitive read on the Compass Phase 3 data becomes important. The conventional assumption in the field has been that the blinding problem, patients and therapists who both know whether a profound psychedelic experience occurred, is psilocybin’s fatal methodological flaw. The Ohio State finding that expectancy did not predict outcome suggests that assumption deserves harder scrutiny. If patients who expected to improve did not improve more than those who did not, the placebo-by-expectancy mechanism looks weaker than critics have claimed. That does not resolve the unblinding problem entirely, but it shifts the burden of proof.

Chris Witowski, co-founder of Psilera, added a layer this week that the approval debate tends to flatten: psilocybin’s pharmacology involves far more than 5-HT2A agonism. Co-administration of buspirone, a 5-HT1A agonist, at 20mg dosed 60 minutes before psilocybin significantly reduced visual effects and oceanic boundlessness in one human trial, attenuating the psychedelic experience itself. A separate study of pindolol, a 5-HT1A antagonist, co-administered with intravenous DMT in a group of 12 experienced users showed synergistic increases in subjective effects alongside significant blood pressure elevation. The polypharmacology is real, it is clinically consequential, and it means that any patient who arrives at a psilocybin clinic already on a psychiatric medication is a pharmacokinetic unknown that no current guideline framework has addressed.

Speyer’s framework of wicked problems is doing real work here. The FDA can approve a molecule. Approval cannot specify what happens when that molecule meets a veteran on high-dose sertraline who has been in therapy for six months, whose therapist has no psychedelic training, whose insurer will cover two sessions, and whose nearest specialized clinic is three states away. That is not a regulatory failure. It is a guideline and infrastructure failure, and it is arriving on a schedule set by the clinical data, which is moving faster than the systems designed to absorb it.

The field spent a decade earning the evidence. The next two years will reveal whether the clinical infrastructure can be built fast enough to honor it. Barba’s timeline, launch in the first half of 2027, is not a distant horizon. It is four budget cycles away for health systems that have not yet begun the conversation.

References

  1. Tommaso Barba, LinkedIn post on Compass Pathways Phase 3 six-month follow-up data, 2025. https://www.linkedin.com/posts/tommaso-barba-88220a177_psilocybin-depression-fda-activity-7490111488444108801-KIel
  2. Alan K. Davis, LinkedIn post on psilocybin-assisted therapy veteran PTSD trial, Communications Medicine, 2025. https://www.linkedin.com/posts/alan-k-davis-phd-b69890361_safety-feasibility-and-preliminary-clinical-activity-7488566008388132864-bHvC
  3. Nathan Sepeda, LinkedIn post on psilocybin PTSD veteran trial results, Johns Hopkins Center for Psychedelic and Consciousness Research, 2025. https://www.linkedin.com/posts/nsepeda_safety-feasibility-and-preliminary-clinical-activity-7488614442599927809-c-v7
  4. Helene Speyer, LinkedIn post on clinical guidelines and wicked problems paper, Region Hovedstadens Psykiatri, 2025. https://www.linkedin.com/posts/helene-speyer-5b73991b4_clinical-guidelines-addressing-complex-and-activity-7489981008226795520-_pGz
  5. Stacey Bradbury Armstrong, LinkedIn post on Ohio State CPDRE psilocybin veteran PTSD trial, Communications Medicine, 2025. https://www.linkedin.com/posts/stacey-bradbury-armstrong_safety-feasibility-and-preliminary-clinical-activity-7488585386152239105-ILyW
  6. Chris Witowski, LinkedIn post on psilocybin polypharmacology and 5-HT1A receptor activity, Psilera, 2025. https://www.linkedin.com/posts/cgwitowski_psychedelics-psilocybin-dmt-activity-7489725742528765952-4nwz
Website |  + posts

Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.